Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Launched by M.D. ANDERSON CANCER CENTER · Dec 30, 2008

Keywords

ClinConnect Summary

This clinical trial is studying patients with Chronic Myelogenous Leukemia (CML) who have been treated with certain medications called tyrosine kinase inhibitors, such as imatinib, dasatinib, and nilotinib, but who are not part of a clinical trial. The researchers want to look at the medical records of these patients to understand how their treatment has worked, especially since many patients are managed differently than those in clinical trials. They will examine various factors, including the effects of treatment interruptions and lower medication doses, as well as the experiences of pregnant patients who have not been included in clinical trials.

If you have CML in any phase and have received treatment with an FDA-approved tyrosine kinase inhibitor outside of a clinical trial, you may be eligible to participate. To take part, you need to have had at least one visit to the MD Anderson Cancer Center (MDACC). Participants can expect the researchers to review their past treatment records, focusing on their experience before and during their visits to MDACC. This study aims to gather important information that can help improve care for patients with CML in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with CML in any phase of the disease (chronic, accelerated or blast phase) that has received treatment with any FDA-approved tyrosine kinase inhibitor (eg, imatinib, dasatinib, nilotinib) not on an MDACC clinical trial regardless of prior treatment history that has had at least one clinic visit at MDACC will be eligible.
• Exclusion Criteria:
• • N/A